[1] Azziz R, Carmina E, Chen Z J, et al. Polycystic ovary syndrome[J]. Nat Rev Dis Primers, 2016, 2: 16057.
[2] Yang R, Li Q, Zhou Z H, et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade[J]. Lancet Reg Health West Pac, 2022, 25: 100494.
[3] Walker K, Decherney A H, Saunders R. Menstrual dysfunction in PCOS[J]. Clin Obstet Gynecol, 2021, 64(1): 119-125.
[4] Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey[J]. Int J Adolesc Med Health, 2021, 33(6): 367-373.
[5] Zhang J H, Hu J, Zhang C X, et al. Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease[J]. Exp Ther Med, 2018, 15(5): 4259-4264.
[6] Li A A, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease[J]. Gut Liver, 2020, 14(2): 168-178.
[7] Holmer M, Melum E, Isoniemi H, et al. Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries[J]. Liver Int, 2018, 38(11): 2082-2090.
[8] Zhang J, Xu J H, Qu Q Q, et al. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: a Meta-analysis of cohort studies[J]. Front Cardiovasc Med, 2020, 7: 552421.
[9] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(1): 19-25.
[10] 中国医疗保健国际交流促进会营养与代谢管理分会,中国营养学会临床营养分会,中华医学会糖尿病学分会,等. 中国超重/肥胖医学营养治疗指南(2021)[J]. 中国医学前沿杂志: 电子版, 2021, 13(11): 1-55.
[11] Chang S, Dunaif A. Diagnosis of polycystic ovary syndrome: which criteria to use and when?[J]. Endocrinol Metab Clin North Am, 2021, 50(1): 11-23.
[12] Khan K A, Stas S, Kurukulasuriya L R. Polycystic ovarian syndrome[J]. J Cardiometab Syndr, 2006, 1(2): 125-130; quiz 131-132.
[13] Wang D X, Nan N, Bing H, et al. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome[J]. Front Endocrinol, 2023, 14: 1241734.
[14] Vrbikova J, Fanta M, Cibula D, et al. Impaired glucose metabolism in women with polycystic ovary syndrome[J]. Gynecol Obstet Invest, 2009, 68(3): 186-190.
[15] Yu J, Zhou Y L, Ding J, et al. Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome[J]. Front Endocrinol, 2022, 13: 970733.
[16] Stener-Victorin E, Baghaei F, Holm G, et al. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial[J]. Fertil Steril, 2012, 97(2): 501-508.
[17] Yousuf S D, Ganie M A, Jeelani S, et al. Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor Ⅷ among women with polycystic ovary syndrome: an observational pilot study[J]. Indian J Med Res, 2018, 148(Suppl): S151-S155.
[18] Kelley C E, Brown A J, Diehl A M, et al. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome[J]. World J Gastroenterol, 2014, 20(39): 14172-14184.
[19] Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?[J]. Endocrine, 2016, 51(2): 211-221.
[20] Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, et al. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis[J]. Hepat Mon, 2014, 14(11): e23235.
[21] Chalasani N, Younossi Z, Lavine J E, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357.
[22] Frias-Toral E, Garcia-Velasquez E, De Los A C M, et al. Polycystic ovary syndrome and obesity: clinical aspects and nutritional management[J]. Minerva Endocrinol, 2022, 47(2): 215-241.
[23] Bizoń A, Franik G, Niepsuj J, et al. The associations between sex hormones and lipid profiles in serum of women with different phenotypes of polycystic ovary syndrome[J]. J Clin Med, 2021, 10(17): 3941.
[24] Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome[J]. Dig Liver Dis, 2015, 47(3): 181-190.
[25] Lonardo A, Nascimbeni F, Mantovani A, et al. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?[J]. J Hepatol, 2018, 68(2): 335-352. |